Why we should not recommend or offer fluvoxamine to COVID-19 patients?
Eur J Clin Pharmacol
.
2023 Feb;79(2):321-322.
doi: 10.1007/s00228-022-03447-3.
Epub 2022 Dec 23.
Author
Vladimir Trkulja
1
Affiliation
1
Department of Pharmacology, Zagreb University School of Medicine, Šalata 11, 10000, Zagreb, Croatia. vladimir.trkulja@mef.hr.
PMID:
36550263
PMCID:
PMC9780092
DOI:
10.1007/s00228-022-03447-3
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19 Drug Treatment
COVID-19*
Fluvoxamine* / therapeutic use
Humans
Patients
Substances
Fluvoxamine